Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR tyrosine kinase inhibitor (TKI) designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation (double mutant) in non-small-cell lung cancer (NSCLC).
Contrary to current opinion, genomic instability is not the origin of cancer in patients with short telomere syndromes (STSs), researchers from the Johns Hopkins University School of Medicine reported April 2, 2023, in Cancer Cell. Instead, short telomeres appeared to cause memory T-cell dysfunction that increased the risk of a small number of tumor types in individuals with STS. Such syndromes can cause premature aging of different physiological systems.
Biomea Fusion Inc. has described GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer, osteoporosis, systemic lupus erythematosus, immunological and inflammatory disorders.
Medshine Discovery Inc. has identified acrylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists reported to be useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
Researchers in Australia have developed new cancer cell line models for pediatric cancers with the lowest survival rates, with a focus on high-risk central nervous system tumors such as glioblastoma.
RSS
